Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. reported that it has entered into a development and manufacturing agreement with a leading U.S.-based Contract Development and Manufacturing Organization to scale up manufacturing for its AAV-based diabetes gene therapy program. The CDMO will provide cGMP-compliant clinical and commercial-ready production and supply drug product for Genprex’s IND-enabling preclinical studies and future clinical trials.
The diabetes candidate delivers the Pdx1 and MafA genes into the pancreas via the pancreatic duct using an AAV vector, with an optimized plasmid construct already cloned, purified and used for AAV manufacture. Preclinical in vivo Type 1 diabetes models showed restoration of normal blood glucose for an extended period, and non-human primate studies indicated reduced insulin needs, higher c-peptide levels and better glucose tolerance. Similar approaches in Type 2 diabetes models demonstrated replenishment and rejuvenation of insulin-producing beta cells. Genprex also notes ongoing work with CDMOs and partners on second-generation AAV and non-viral lipid nanoparticle delivery, and reiterates that all development timelines and outcomes remain subject to significant risks and uncertainties.
Genprex, Inc., a clinical-stage gene therapy company, reported a Q2 2026 net loss of $4.45 million, slightly improved from $4.67 million a year earlier, and a six‑month net loss of $8.91 million. The company has no revenue and total operating expenses for the first half were $8.98 million.
Cash and cash equivalents rose to $15.15 million at June 30, 2026 from $7.83 million at year-end 2025, driven mainly by $15.6 million of equity raised under an at‑the‑market facility. Total assets were $17.14 million with modest liabilities of $2.34 million.
Management states there is substantial doubt about the ability to continue as a going concern, even though current cash is expected to fund operations into the second half of 2027, and additional capital will be required. Genprex continues advancing its REQORSA gene therapy in Phase 2 portions of the Acclaim‑1 and Acclaim‑3 lung cancer trials, both with FDA Fast Track Designation and Acclaim‑3 also holding Orphan Drug Designation. The diabetes gene therapy program remains in preclinical development following FDA feedback on IND‑enabling studies. Capital structure was affected by a 1‑for‑50 reverse split in 2025 and a subsequent 1‑for‑22 reverse split in July 2026, with 506,218 shares outstanding at June 30, 2026 and 819,709 shares reported as of August 10, 2026.
Genprex, Inc. reported that a Nasdaq Hearings Panel has formally determined the company has regained compliance with the Nasdaq Capital Market $1.00 Minimum Bid Price requirement under Listing Rule 5550(a)(2). This follows the Panel’s earlier decision granting Genprex an exception to work toward compliance.
The company must now maintain a closing bid price at or above $1.00 for every trading day through December 7, 2026, which is the full extent of the Panel’s discretion on this matter. The Panel will retain jurisdiction over Genprex until that date. If the company becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it will have seven calendar days to present a plan to cure the deficiency, after which the Panel may either permit additional time for compliance or move to delist the company.
Genprex, Inc. reported a new collaboration with Roche Diagnostics to validate biomarkers for selecting non-small cell lung cancer (NSCLC) patients in clinical trials. The work focuses on TROP2 and PTEN, building on data showing that high TROP2 H-scores and low PTEN H-scores predicted patient response in preclinical studies and were associated with longer Progression Free Survival in clinical studies for NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100.
The collaboration uses Roche’s assay-development capabilities and its TROP2 antibody, which underlies an AI-driven NSCLC companion diagnostic that has received FDA Breakthrough Device Designation. Roche will perform assay validation with this antibody, and Genprex anticipates completing validation studies by approximately the end of 2026, with potential integration of TROP2-based patient selection into its NSCLC clinical program thereafter, depending on validation results. Genprex frames this as part of its strategy to enable more precise, biomarker-guided treatment for NSCLC.
Genprex, Inc. received a conditional extension from a Nasdaq Hearings Panel to keep its common stock listed on The Nasdaq Capital Market under an exception to the $1.00 minimum bid price requirement. The exception requires Genprex to evidence compliance with the bid-price rule by July 29, 2026 and then maintain a closing bid of at least $1.00 on every trading day through December 7, 2026, during which period the Panel retains jurisdiction and may impose a discretionary monitor.
Genprex adds a risk-factor update explaining that it has implemented a 1-for-22 reverse stock split, effective July 16, 2026, as a step toward compliance, but warns this action may pressure its share price and reduce trading liquidity. The company highlights that it must also satisfy other Nasdaq standards, including minimum stockholders’ equity of $2.5 million, and notes a July 22, 2026 Nasdaq rule change under which failure to maintain a market value of listed securities of at least $5 million for 30 consecutive business days would result in immediate suspension and delisting. Genprex cautions that any delisting could materially depress its stock price and hinder access to capital.
Genprex, Inc. approved a one-for-twenty-two Reverse Stock Split of its common stock, effective at 12:01 a.m. Eastern Time on July 16, 2026. Every 22 outstanding shares will convert into 1 share, with fractional positions rounded up to the next whole share. Based on 11,108,577 shares outstanding on July 13, 2026, Genprex estimates about 504,936 shares will be outstanding after the split. The split does not change par value or authorized share count, and outstanding options and warrants will be proportionally adjusted.
The company is using this split as part of efforts to address Nasdaq’s $1.00 minimum bid price requirement after receiving a June 10, 2026 delisting notice and requesting a hearing before a Nasdaq panel. Genprex cautions that the split may not restore compliance and could negatively affect share price, liquidity and market capitalization, with delisting potentially impairing capital-raising ability and overall business.
The company also highlights progress in its REQORSA gene therapy lung cancer program, including ongoing Phase 2 expansion enrollment in the Acclaim-1 and Acclaim-3 trials, FDA Fast Track and Orphan Drug designations, and emerging biomarker data (TROP-2 and PTEN) that may guide patient selection and optimize outcomes.
Genprex, Inc. reports that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering the use of REQORSA Gene Therapy (quaratusugene ozeplasmid) with PD-1 or PD-L1 antibodies to treat both non-small cell and small cell lung cancer. This patent builds on earlier REQORSA combination patents already granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia and Israel, further reinforcing the company’s global intellectual property position. Genprex believes the Canadian patent provides important protection for therapeutic combinations now being evaluated in the Acclaim-3 clinical trial. The company highlights Canadian Cancer Society data showing lung and bronchus cancer is the most commonly diagnosed cancer in Canada and the leading cause of cancer death, underscoring the potential need for new treatment options.
Genprex, Inc. reported results from its 2026 annual stockholders meeting, where investors approved an Amended and Restated 2018 Equity Incentive Plan adding 1,850,000 shares of common stock for potential equity awards. The plan now runs through April 15, 2036.
Stockholders also re-elected Jose Antonio Moreno Toscano and Ryan M. Confer as Class III directors and ratified WithumSmith+Brown, PC as auditor for the year ending December 31, 2026. An advisory vote approved compensation for named executive officers.
Shareholders further authorized an amendment to the certificate of incorporation allowing a reverse stock split at a ratio between 1-for-5 and 1-for-50, which the board may implement at its discretion any time before December 31, 2027.
Genprex, Inc. reported that Nasdaq has determined to delist its common stock after the shares closed below $1.00 for 30 consecutive business days, violating the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. Because Genprex executed a reverse stock split on October 21, 2025, it is not eligible for a standard 180-day compliance period under Listing Rule 5810(c)(3)(A)(iv). The company plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action during the process and any extension period the Panel may grant.
Genprex added a risk factor explaining that failure to regain and maintain compliance with Nasdaq’s continued listing standards could lead to delisting, potentially harming its stock price, liquidity, and ability to access capital markets. The company states it intends to take definitive steps to meet the bid price requirement, including considering another reverse stock split if appropriate, while cautioning there is no assurance of success and noting possible negative effects of a reverse split on price and liquidity.
Genprex, Inc. is registering a shelf offering to sell up to $250,000,000 of securities, which may include common stock, preferred stock, warrants, debt securities, subscription rights and units, pursuant to a prospectus dated June 5, 2026.
The filing replaces a prior registration and includes $76,143,570.21 of unsold securities carried forward from the prior registration. The prospectus discloses a public float of $15,812,904 (based on 10,905,451 non-affiliate shares at $1.45) and states that net proceeds will be used for working capital and general corporate purposes.